# Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer

> **NCT00272649** · PHASE1,PHASE2 · COMPLETED · sponsor: **Argos Therapeutics** · enrollment: 22 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** AGS-003

## Key facts

- **NCT ID:** NCT00272649
- **Lead sponsor:** Argos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2013-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00272649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00272649, "Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00272649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*